Livzon Pharmaceutical Group Inc(000513) : the research and development of variant vaccine against Omicron has been carried out

Livzon Pharmaceutical Group Inc(000513) (000513) said during the investigation that the company’s covid-19 vaccine v-01 is a recombinant protein vaccine. At present, the research and development of mutant vaccine against Omicron has been carried out. Lizhu’s covid-19 vaccine v-01 has been in phase III clinical trials in many overseas countries, and will strive for the opportunity to be listed and sold overseas in the future. Although the vaccination rate of covid-19 vaccine in China has been very high, and some provinces have successively started the vaccination of booster needles, the company also expects v-01 to be listed in China as booster needles as soon as possible.